Novel Anti-inflammatory Mechanism of Elafin
Proteo, Inc. and its wholly-owned subsidiary Proteo Biotech AG announced that the team of Prof. Noel McElvaney at the Respiratory Research Division, Royal College of Surgeons in Dublin, is focused on the research in the field of inflammatory pulmonary diseases, particularly of cystic fibrosis. The team has shown that Elafin is able to abrogate lipopolysaccharide-induced production of monocyte chemotactic protein 1 in monocytes by inhibiting AP-1 and NFkappaB activation. The authors conclude that due to its selective Expression at mucosal surfaces as well as in alveolar macrophages, monocytes and neutrophils, the ability of Elafin to inhibit the lipopolysaccharide signaling pathway may be important in disease states such as cystic fibrosis, pneumonia, and acute respiratory distress syndrome. According to the company, the inhibition of two key inflammatory pathways confirms the importance of Elafin as a mediator of the innate immune response.
Original publication: Butler MW, Robertson I, Greene CM, O'Neill SJ, Taggart CC, McElvaney NG.; "Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway."; J Biol Chem. 2006; 281: 34730-5.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
